A multicenter, double-blind, randomized study to evaluate the safety and efficacy of sitagliptin compared with metformin in patients with type 2 diabetes mellitus with inadequate glycemic control.

Trial Profile

A multicenter, double-blind, randomized study to evaluate the safety and efficacy of sitagliptin compared with metformin in patients with type 2 diabetes mellitus with inadequate glycemic control.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2017

At a glance

  • Drugs Sitagliptin (Primary) ; Metformin; Metformin/sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Nov 2012 Planned number of patients changed from 1000 to 1034.
    • 11 Sep 2008 Results from the 50-week extension phase presented at EASD
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top